Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 9, 2003

View Archived Issues

Genome Therapeutics and Amgen to develop novel therapeutics for bone diseases

PDI to commercialize Cellegy's Tostrex in North America

Finacea approved for topical treatment of rosacea

Recent progress in Vertex programs reviewed

Pfizer launches three-day antibiotic for middle ear infections

FDA approves Clozaril to reduce the risk of suicidal behavior

Etilevodopa fails to meet primary objective in phase III trials

FDA approves Singulair for seasonal allergic rhinitis

European approval received for use of Glivec as first-line treatment in CML

Proof of concept established in patients for Arachnova's product for dermatitis

Clinical testing begins for first oral TPO growth factor

Prozac approved for pediatric depression and OCD

Experimental acute pancreatitis in mice improved by adenosine uptake inhibitor KF-24345

Panacea extends collaboration for HAAH oncology program

Initiation of phase IV trial of Periostat and Atridox combination therapy

Velac enters phase III development program for acne

Phase II trial of Veronate for prevention of staph infections in premature infants under way

Roche claims novel NPY Y5 antagonists for obesity and other disorders

New series of monoamine reuptake inhibitors identified at NeuroSearch

Pharmacia selects backup compound to LTA4 hydrolase inhibitor SC-57461A

Merck Frosst scientists discover novel prostaglandin D2 receptor antagonists

Sodium channel modulators claimed by Gruenenthal for pain and other uses

Novel agents for mycobacterial and viral infections prepared and tested at Axxima

New TNF-alpha production inhibitors discovered by Celgene

Preclinical profile of a potent, selective, centrally acting and orally active NK1 antagonist

Advances reported in Scios's p38 MAP kinase program

Endo licenses rights from SkyePharma for two critical care products

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...